Trial Profile
A Pilot Phase II Study of a Nucleoside Sparing Regimen of Dolutegravir + Atazanavir/r in HIV-1 Infected Patients With Detectable Viremia (DOLATAV Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary) ; Dolutegravir (Primary) ; Ritonavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms Dolatav
- 11 Aug 2021 Status changed from recruiting to completed.
- 24 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 08 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.